

Table 1. Baseline characteristics of patients in sarcopenia group and non-sarcopenia group before and after PSM matching.

Characteristics	Before matching (N=267)		P-value	After 1:2 matching (N=201)		P-value
	Sarcopenia group (N=88)	Non-sarcopenia group (N=179)		Sarcopenia group (N=77)	Non-sarcopenia group (N=124)	
Age (years) ^a	67.20±8.77	61.98±9.39	0.540	66.18±8.67	64.49±8.74	0.181
ALT (IU/L) ^b	20.5 (14, 30)	19 (14, 28)	0.408	19 (13, 27.5)	21 (14, 30)	0.576
AST (IU/L) ^b	24.5 (20, 36)	24 (20, 31)	0.343	24 (19, 32)	26 (21, 32)	0.302
ALP (IU/L) ^b	91 (74, 116.25)	82 (65, 111)	0.046*	88 (70.5, 110.5)	84 (66, 111)	0.464
LDH (IU/L) ^b	225 (188.25, 306)	242 (193, 314)	0.451	216 (183.5, 284)	241 (191, 309)	0.182
Total bilirubin (μmol/L) ^b	9.45 (7.63, 13.35)	9.5 (7.1, 12.3)	0.383	9.5 (7.85, 3.15)	9.9 (7.2, 13.1)	0.614
Direct bilirubin (μmol/L) ^b	2.95 (1.73, 4.30)	2.3 (1.4, 3.2)	0.008*	2.6 (1.7, 4.1)	2.4 (1.7, 3.7)	0.299
D-dimer (mg/L) ^b	0.76 (0.45, 1.36)	0.76 (0.43, 1.65)	0.937	0.75 (0.45, 1.33)	0.76 (0.44, 1.65)	0.896
PT (sec) ^b	11.5 (11, 12.4)	11.4 (10.8, 11.9)	0.054	11.5 (11, 12.5)	11.4 (10.7, 12.1)	0.072
APTT (sec) ^b	28.25 (27.03, 29.35)	28.1 (26.5, 29.6)	0.260	28.3 (26.9, 29.55)	28 (26.5, 29.3)	0.199
BUN (mmol/L) ^b	6.1 (4.9, 7.2)	5.6 (4.6, 6.9)	0.176	6.1 (4.9, 7.05)	5.8 (4.7, 7.2)	0.935
Cr (μmol/L) ^b	68 (60.5, 81.25)	67 (56, 75)	0.164	69 (61, 78.5)	69 (59, 78)	0.521
WBC (10 ⁹ /L) ^b	5.9 (4.5, 7.4)	5.8 (4.8, 7.6)	0.751	5.6 (4.35, 7.3)	5.9 (4.8, 7.7)	0.168
Hemoglobin (g/L) ^a	118.0±19.4	120.8±18.6	0.735	119.03±19.59	119.98±18.47	0.742
PLT (10 ⁹ /L) ^b	195.5 (148.5, 247.8)	210 (168, 262)	0.068	196 (147.5, 240)	200 (160, 263)	0.107
Neutrophils (10 ⁹ /L) ^b	3.97 (2.83, 5.15)	3.66 (2.76, 5.13)	0.609	3.54 (2.64, 4.92)	3.69 (2.76, 5.17)	0.534
Lymphocyte (10 ⁹ /L) ^b	1.18 (0.86, 1.51)	1.35 (1.02, 1.57)	0.023*	1.18 (0.87, 1.54)	1.33 (0.93, 1.56)	0.170
NLR ^b	3.33 (2.12, 4.92)	2.81 (2.02, 4.42)	0.053	3.12 (2.07, 4.35)	2.94 (2.05, 5.06)	0.644
PLR ^b	164.44 (116.71, 224.67)	164.10 (114.76, 227.43)	0.880	160.63 (114.68, 210.14)	165.97 (111.68, 241.01)	0.675
Total cholesterol (mmol/L) ^b	4.2 (3.6, 4.9)	4.3 (3.7, 4.8)	0.765	4.2 (3.5, 4.8)	4.3 (3.8, 4.8)	0.378
Triglycerides (mmol/L) ^b	1.21 (0.92, 1.70)	1.37 (0.96, 1.71)	0.374	1.2 (0.92, 1.62)	1.37 (0.94, 1.74)	0.367
HDL (mmol/L) ^b	1.08 (0.85, 1.27)	1.06 (0.91, 1.26)	0.789	1.09 (0.86, 1.26)	1.06 (0.92, 1.25)	0.951
LDL (mmol/L) ^a	2.77±0.77	2.74±0.71	0.160	2.74±0.79	2.79±0.67	0.720
Albumin (g/L) ^a	38.50±5.36	39.24±5.06	0.632	38.92±5.20	38.96±5.13	0.975
Globulin (g/L) ^b	29.55 (27.00, 34.35)	29.3 (26.8, 32.6)	0.407	29.7 (27, 34.3)	29.5 (26.4, 32.2)	0.252
A/G ^b	1.25 (1.07, 1.48)	1.33 (1.14, 1.47)	0.169	1.25 (1.08, 1.51)	1.33 (1.13, 1.46)	0.365
Serum CEA(ng/mL) ^b	9.50 (4.20, 45.53)	8.75 (3.18, 39.08)	0.532	7.9 (4.05, 43.9)	8.3 (3.1, 35.2)	0.611
Gender (Male), n(%)			0.178			0.692
-Male	61 (69.3%)	109 (60.9%)		53 (68.8%)	82 (66.1%)	

-Female	27 (30.7%)	70 (39.1%)		24 (31.2%)	42 (33.9%)	
Smoking history, n(%)			0.602			0.649
-Yes	8 (9.1%)	20 (11.2%)		6 (7.8%)	12 (9.7%)	
-No	80 (90.9%)	159 (88.8%)		71 (92.2%)	112 (90.3%)	
Hypertension, n(%)			0.272			0.667
-Yes	24 (27.3%)	38 (21.2%)		22 (28.6%)	32 (25.8%)	
-No	64 (72.7)	141 (78.8)		55 (71.4)	92 (74.2%)	
Diabetes, n(%)			0.709			0.489
-Yes	7 (8.0%)	12 (6.7%)		7 (9.1%)	8 (6.5%)	
-No	81 (92.0%)	167 (93.3%)		70 (90.9)	116 (93.5%)	
Pleural effusion, n(%)			0.904			0.968
-Yes	41 (46.6%)	82 (45.8%)		35 (45.5%)	55 (45.2%)	
-No	47 (53.4%)	97 (54.2%)		42 (54.5%)	69 (54.8%)	
ECOG score, n(%)			0.510			0.715
-≥2	9 (10.2%)	14 (7.8%)		4 (5.2%)	8 (6.5%)	
-0~1	79 (89.8%)	165 (92.2%)		73 (94.8%)	116 (93.5%)	
KPS score, n(%)			0.205			0.071
-<60	3 (3.4%)	1 (0.6%)		2 (2.6%)	0 (0%)	
-≥60	85 (96.6%)	178 (99.4%)		75 (97.4)	124 (100%)	
Urine protein, n(%)			0.887			0.580
-Yes	1 (1.1%)	4 (2.2%)		1 (1.3%)	3 (2.4%)	
-No	87 (98.9%)	175 (97.8%)		76 (98.7%)	121 (97.6%)	
BMI (kg/m ²), n(%)			0.458			0.556
≥24	26 (29.5%)	61 (34.1%)		23 (29.9%)	42 (33.9%)	
<24	62 (70.5%)	118 (65.9%)		54 (70.1%)	82 (66.1%)	
NRS-2002 score, n(%)			0.137			0.539
≥3	18 (20.5%)	24 (13.4%)		13 (16.9%)	17 (13.7%)	
<3	70 (79.5%)	155 (86.6%)		64 (83.1%)	107 (86.3%)	
Pathological type			0.086			0.299
-Adenocarcinoma, n(%)	66 (75.0%)	150 (83.8%)		58 (75.3%)	101 (81.5%)	
-Non-adenocarcinoma, n(%)	22 (25.0%)	29 (16.2%)		19 (24.7%)	23 (18.5%)	
TNM stage			0.468			0.661
-IIIa, n(%)	3 (3.4%)	6 (3.4%)		3 (3.9%)	5 (4.0%)	
-IIIb, n(%)	4 (4.5%)	3 (1.7%)		3 (3.9%)	3 (2.4%)	

-IIIc, n(%)	0 (0.0%)	2 (1.1%)		0 (0.0%)	2 (1.6%)	
-IV, n(%)	81 (92.0%)	168 (93.9%)		71 (92.2%)	114 (91.9%)	
Previous treatment						
-Chemotherapy, n(%)	78 (88.6%)	157 (87.7%)	0.826	70 (90.9%)	107 (86.3%)	0.326
-Targeted therapy, n(%)	24 (27.3%)	69 (38.5%)	0.069	23 (29.9%)	47 (37.9%)	0.245
-Immunotherapy, n(%)	29 (33.0%)	47 (26.3%)	0.254	27 (35.1%)	38 (30.6%)	0.515
-Radiotherapy, n(%)	3 (3.4%)	11 (6.1%)	0.346	3 (3.9%)	9 (7.3%)	0.328
-Surgical treatment, n(%)	11 (12.5%)	25 (14.0%)	0.742	10 (13%)	19 (15.3%)	0.647

Continuous variables^a with normal distribution are presented as mean value $\pm$ SD while others^b are presented as median (IQR). Categorical variables are presented as frequency(percentage) unless otherwise stated.